Understanding How Breast Cancer Patients Use Risk Information from Genomic Tests

Overview

Journal J Behav Med

Specialty Social Sciences

Date 2012 Aug 11

PMID 22878783

Citations 10

Authors

Jessica T DeFrank

Lisa A Carey

Noel T Brewer

Affiliations

Soon will be listed here.

Abstract

We sought to examine how patients' treatment decisions incorporate potentially conflicting information from standard clinical indicators (e.g., tumor size) and genomic tests for breast cancer recurrence risk. Participants were 77 early stage breast cancer survivors who previously received genomic testing. They read six hypothetical vignettes that varied recurrence risk indicated by standard tests (low or high risk) coupled with the genomic test (low, intermediate or high risk). For each vignette, women reported their perceived recurrence risk and treatment preferences. Test results indicating high recurrence risk increased perception of risk and preference for chemotherapy (p < .001 for all). Perceived risk explained (i.e., mediated) the effect of test results on chemotherapy preferences. When test results conflicted, women gave more weight to genomic over standard test results. Hypothetical genomic test results had the intended effect of influencing women's perceptions of recurrence risk and interest in chemotherapy.

Citing Articles

Patients' perceptions of 70-gene signature testing: commonly changing the initial inclination to undergo or forego chemotherapy and reducing decisional conflict.

van Steenhoven J, den Dekker B, Kuijer A, van Diest P, Nieboer P, Zuetenhorst J Breast Cancer Res Treat. 2020; 182(1):107-115.

PMID: 32430679 PMC: 7275022. DOI: 10.1007/s10549-020-05683-6.

Genomics and Infectious Diseases: Expert Perspectives on Public Health Considerations regarding Actionability and Privacy.

Walker A, Boyce A, Duggal P, Thio C, Geller G Ethics Hum Res. 2020; 42(3):30-40.

PMID: 32421947 PMC: 7276751. DOI: 10.1002/eahr.500051.

Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.

Ont Health Technol Assess Ser. 2020; 20(10):1-234.

PMID: 32284770 PMC: 7143374.

Which self-management strategies do health care professionals recommend to their cancer patients? An experimental investigation of patient age and treatment phase.

Ungar N, Schmidt L, Gabrian M, Haussmann A, Tsiouris A, Sieverding M J Behav Med. 2018; 42(2):342-352.

PMID: 30353398 DOI: 10.1007/s10865-018-9980-1.

The PiGeOn project: protocol of a longitudinal study examining psychosocial and ethical issues and outcomes in germline genomic sequencing for cancer.

Best M, Newson A, Meiser B, Juraskova I, Goldstein D, Tucker K BMC Cancer. 2018; 18(1):454.

PMID: 29685123 PMC: 5914013. DOI: 10.1186/s12885-018-4366-x.

References

Gurmankin A, Domchek S, Stopfer J, Fels C, Armstrong K . Patients' resistance to risk information in genetic counseling for BRCA1/2. Arch Intern Med. 2005; 165(5):523-9. DOI: 10.1001/archinte.165.5.523. View

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S . American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25(33):5287-312. DOI: 10.1200/JCO.2007.14.2364. View

Brewer N, Edwards A, ONeill S, Tzeng J, Carey L, Rimer B . When genomic and standard test results diverge: implications for breast cancer patients' preference for chemotherapy. Breast Cancer Res Treat. 2008; 117(1):25-9. DOI: 10.1007/s10549-008-0175-2. View

Habel L, Shak S, Jacobs M, Capra A, Alexander C, Pho M . A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 2006; 8(3):R25. PMC: 1557737. DOI: 10.1186/bcr1412. View

Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J . Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol. 2005; 23(29):7265-77. DOI: 10.1200/JCO.2005.02.0818. View

Brewer N, Cuite C, Herrington J, Weinstein N . Risk compensation and vaccination: can getting vaccinated cause people to engage in risky behaviors?. Ann Behav Med. 2007; 34(1):95-9. DOI: 10.1007/BF02879925. View

Richman A, Tzeng J, Carey L, Retel V, Brewer N . Knowledge of genomic testing among early-stage breast cancer patients. Psychooncology. 2010; 20(1):28-35. DOI: 10.1002/pon.1699. View

Oratz R, Paul D, Cohn A, Sedlacek S . Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. J Oncol Pract. 2010; 3(4):182-6. PMC: 2793805. DOI: 10.1200/JOP.0742001. View

Lerman C, Hughes C, Croyle R, Main D, Durham C, Snyder C . Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med. 2000; 31(1):75-80. DOI: 10.1006/pmed.2000.0684. View

10.

Paik S . Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist. 2007; 12(6):631-5. DOI: 10.1634/theoncologist.12-6-631. View

11.

van de Vijver M, He Y, Vant Veer L, Dai H, Hart A, Voskuil D . A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347(25):1999-2009. DOI: 10.1056/NEJMoa021967. View

12.

ONeill S, Brewer N, Lillie S, Morrill E, Dees E, Carey L . Women's interest in gene expression analysis for breast cancer recurrence risk. J Clin Oncol. 2007; 25(29):4628-34. DOI: 10.1200/JCO.2006.09.6255. View

13.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

14.

Guttmacher A, Collins F . Genomic medicine--a primer. N Engl J Med. 2002; 347(19):1512-20. DOI: 10.1056/NEJMra012240. View

15.

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W . Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24(23):3726-34. DOI: 10.1200/JCO.2005.04.7985. View

16.

Morris S, Carey L . Gene expression profiling in breast cancer. Curr Opin Oncol. 2007; 19(6):547-51. DOI: 10.1097/CCO.0b013e3282f0ada3. View

17.

Dowsett M, Cuzick J, Wale C, Forbes J, Mallon E, Salter J . Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010; 28(11):1829-34. DOI: 10.1200/JCO.2009.24.4798. View

18.

Baron R, Kenny D . The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986; 51(6):1173-82. DOI: 10.1037//0022-3514.51.6.1173. View

19.

Oratz R, Kim B, Chao C, Skrzypczak S, Ory C, Bugarini R . Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer. J Oncol Pract. 2011; 7(2):94-9. PMC: 3051869. DOI: 10.1200/JOP.2010.000046. View

20.

Schwartz L, Woloshin S, Black W, Welch H . The role of numeracy in understanding the benefit of screening mammography. Ann Intern Med. 1997; 127(11):966-72. DOI: 10.7326/0003-4819-127-11-199712010-00003. View